Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years.

Trial Profile

Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis; Encephalitis virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PRTBEIS
  • Sponsors Baxter Vaccines
  • Most Recent Events

    • 13 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top